secwatch.observer — SEC 8-K summary
======================================

Issuer:     Arcturus Therapeutics Holdings Inc. (ARCT)
CIK:        0001768224
Form:       8-K
Filed at:   2023-05-09T23:59:59+00:00
Accession:  0001193805-23-000686
Event type: earnings
Sentiment:  positive
Materiality: 0.75
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Arcturus Q1 net income $50.8M ($1.87 EPS) vs loss year ago; NDA filed for COVID vaccine ARCT-154 in Japan
--------------------------------------------------------------------------------

- Revenue $80.3M (up from $5.2M YoY) driven by CSL Seqirus milestones; net income $50.8M vs loss of $51.2M.
- NDA for ARCT-154 (COVID-19 vaccine) submitted in Japan by Meiji Seika Pharma; potential approval later 2023.
- Cash $330.1M; long-term debt eliminated; expects $90M AR collection in Q2; runway extended into early 2026.
- ARCT-032 Phase 1 enrollment complete; expansion to CF patients planned Q3 2023. ARCT-810 Phase 2 interim data on track for later 2023.
- Received $23.6M advance from CSL Seqirus for manufacturing and supply of ARCT-154 in April.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1768224/000119380523000686/0001193805-23-000686-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1768224/000119380523000686/e618600_8k-arct.htm
  HTML page:      https://secwatch.observer/filing/0001193805-23-000686

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer